{
    "eid": "2-s2.0-85129139664",
    "title": "Dynamics of Neutralizing Antibody and T-Cell Responses to SARS-CoV-2 and Variants of Concern after Primary Immunization with CoronaVac and Booster with BNT162b2 or ChAdOx1 in Health Care Workers",
    "cover-date": "2022-05-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Immunology",
            "@code": "2403",
            "@abbrev": "IMMU"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology",
            "@code": "3004",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Drug Discovery",
            "@code": "3002",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology (medical)",
            "@code": "2736",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "anti-SARS-CoV-2 spike total antibodies",
        "BNT162b2",
        "booster",
        "ChAdOx1",
        "CoronaVac",
        "COVID-19",
        "SARS-CoV-2",
        "surrogate viral neutralizing antibody",
        "T-cell immune response",
        "vaccines"
    ],
    "authors": [
        "Watsamon Jantarabenjakul",
        "Pimpayao Sodsai",
        "Napaporn Chantasrisawad",
        "Anusara Jitsatja",
        "Sasiprapa Ninwattana",
        "Nattakarn Thippamom",
        "Vichaya Ruenjaiman",
        "Chee Wah Tan",
        "Rakchanok Pradit",
        "Jiratchaya Sophonphan",
        "Supaporn Wacharapluesadee",
        "Lin Fa Wang",
        "Thanyawee Puthanakit",
        "Nattiya Hirankarn",
        "Opass Putcharoen"
    ],
    "citedby-count": 16,
    "ref-count": 35,
    "ref-list": [
        "Short-term immune response after inactivated SARS-CoV-2 (CoronaVac(R), Sinovac) and ChAdOx1 nCoV-19 (Vaxzevria(R), Oxford-AstraZeneca) vaccinations in health care workers",
        "SARS-CoV-2 Variants and Vaccines",
        "mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant",
        "Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization",
        "Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): A single-blind, randomised, non-inferiority trial",
        "Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine",
        "Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: Interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials",
        "Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine",
        "SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen",
        "Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): A phase 4, non-inferiority, single blind, randomised study",
        "An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey",
        "Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults",
        "A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction",
        "Clinical Utility of Elecsys Anti-SARS-CoV-2 S Assay in COVID-19 Vaccination: An Exploratory Analysis of the mRNA-1273 Phase 1 Trial",
        "Suggested guidelines for convalescent plasma therapy for the treatment of COVID-19",
        "Neutralization assays for differential henipavirus serology using Bio-Plex Protein Array Systems",
        "Deconvoluting the T Cell Response to SARS-CoV-2: Specificity Versus Chance and Cognate Cross-Reactivity",
        "Peculiarities of the T Cell Immune Response in COVID-19",
        "Immunogenicity of ChAdOx1 nCoV-19 Booster Vaccination Following Two CoronaVac Shots in Healthcare Workers",
        "Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination",
        "Immunogenicity of heterologous BNT162b2 booster in fully vaccinated individuals with CoronaVac against SARS-CoV-2 variants Delta and Omicron: The Dominican Republic Experience",
        "Immunological mechanisms of vaccine-induced protection against COVID-19 in humans",
        "WHO international standard for SARS-CoV-2 antibodies to determine markers of protection",
        "Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine",
        "SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19",
        "T cell responses to SARS-CoV-2 spike cross-recognize Omicron",
        "Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron",
        "Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection",
        "Omicron SARS-CoV-2 variant: Unique features and their impact on pre-existing antibodies",
        "Heterologous prime-boost: Breaking the protective immune response bottleneck of COVID-19 vaccine candidates",
        "Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine",
        "Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): A blinded, multicentre, randomised, controlled, phase 2 trial",
        "SARS-CoV-2 T-cell immunity to variants of concern following vaccination"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Singapore City",
            "@id": "60095034",
            "affilname": "Duke-NUS Medical School",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60095034",
            "affiliation-country": "Singapore"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60031780",
            "affilname": "Thai Red Cross Agency",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60031780",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "CREID",
        "Rachadaphiseksomphot Fund",
        "NIH",
        "NIAID",
        "King Chulalongkorn Memorial Hospital Fund",
        "National Medical Research Council",
        "Chulalongkorn University",
        "National Research Council of Thailand",
        "Faculty of Medicine, Chulalongkorn University"
    ]
}